How FIB-4 Differs from APRI
FIB-4 consistently outperforms APRI for detecting advanced fibrosis and cirrhosis across most chronic liver disease etiologies, particularly in NAFLD/MASLD, making it the preferred first-line noninvasive test. 1, 2
Key Compositional Differences
The fundamental distinction lies in their formulas:
- APRI = (AST/upper limit of normal) × 100 / platelet count
- FIB-4 = (Age × AST) / (platelet count × √ALT)
FIB-4 incorporates age and ALT in addition to AST and platelets, making it more comprehensive. This age adjustment is particularly important since fibrosis progression correlates with duration of disease exposure 2.
Comparative Diagnostic Performance
For Advanced Fibrosis (F3-4) in NAFLD
The 2025 AASLD systematic review demonstrates FIB-4's superiority 1:
- FIB-4 at cutoff 2.67: DOR of 9.98 (6.94-14.36)
- APRI at cutoff 1.0: DOR of 8.48 (6.74-10.66)
In direct head-to-head comparisons across 86 studies, FIB-4 <1.45 outperformed APRI <0.5 for ruling out significant fibrosis (F0-1 vs F2-4), and FIB-4 >3.25 was superior to APRI >1.5 for detecting advanced fibrosis 1.
Exception: Recent MASLD Data
One 2025 Korean study of 2,843 patients found APRI had slightly higher AUC values than FIB-4 in MASLD (0.818 vs 0.778 for F≥2), particularly in younger patients 3. However, this contradicts the broader guideline evidence and may reflect population-specific characteristics.
Clinical Application Differences
Rule-Out Capability
FIB-4 is specifically recommended by EASL 2021 guidelines as the preferred "gate-keeping test" in primary care for low-prevalence populations 2. Its simplicity and superior performance in head-to-head comparisons make it ideal for:
- Screening patients with type 2 diabetes
- Risk stratification in metabolic syndrome
- Initial evaluation in primary care settings
Cutoff Considerations
Both tests require AST-stratified cutoffs to avoid overestimation from necroinflammatory activity 4:
For patients with normal AST (≤37 IU/L):
- APRI optimal cutoff: 0.6 for cirrhosis
- FIB-4 optimal cutoff: 1.4 for cirrhosis
For elevated AST (>148 IU/L):
- APRI optimal cutoff: 3.4 for cirrhosis
- FIB-4 optimal cutoff: 5.5 for cirrhosis
Etiology-Specific Performance
Hepatitis C
FIB-4 was originally developed for HIV/HCV coinfection and maintains strong performance 1. In post-transplant HCV patients, FIB-4 provided better AUROC (0.711) than APRI (0.693) 5.
HIV/HBV Coinfection
Both tests show comparable accuracy when compared to transient elastography, with FIB-4 >1.5 having 95.2% PPV and APRI >0.5 having 98.2% PPV 6. Either can be used reliably in resource-limited settings.
Chronic Hepatitis B
FIB-4 demonstrates higher sensitivity (71% vs 34%) though APRI has better specificity (79% vs 46%) at optimal cutoffs 7. For CHB specifically, FIB-4's higher sensitivity makes it preferable for ruling out fibrosis.
Practical Implementation
The 2021 EASL guidelines explicitly state that FIB-4 "is simpler to calculate and performs better than other simple NITs in head-to-head comparisons, particularly in NAFLD" 2. This recommendation supports:
- Automatic FIB-4 calculation when liver blood tests are ordered
- Use of FIB-4 as the first-tier test in two-step algorithms
- Routine measurement of AST, ALT, and platelet count in primary care
Critical Caveats
Both tests are indirect markers of liver damage, not direct fibrosis markers 2. They should not be used as singular decision tools. If clinical suspicion remains despite normal values, proceed to more accurate testing (elastography or biopsy). Both tests lose accuracy in populations without proper risk stratification or in unselected populations where differential diagnoses broaden 2.